Novo Nordisk's Implant Gambit: Can a Device and a China Filing Rebuild Investor Confidence?

Novo Nordisk trades at P/E of 11 amid China filing, Vivani implant deal, and Lilly lawsuit; shares down 28% from January peak.

When a pharmaceutical heavyweight trades at a single-digit forward earnings multiple while its pipeline is arguably broader than ever, the market is pricing in something beyond near-term execution risk. That is the position Novo Nordisk finds itself in this month, as the Danish drugmaker juggles a regulatory filing in China, a novel drug-delivery partnership, and a legal spat with its chief rival — all while its shares sit roughly 28 percent below January's peak.

The stock closed Friday at EUR 39.41, down 0.6 percent on the day. Over the past month, the equity has shed 13 percent, and it remains 10 percent in the red since the start of the year. The 52-week high of EUR 54.86, touched in January, now looks distant. Yet the company's recent moves suggest management is not content to let the narrative drift.

A Device to Eliminate the Needle

Among the more intriguing developments is a potential collaboration with Vivani Medical, disclosed in an investor presentation, to develop an implantable device that would automatically administer Wegovy. The concept would free patients from the weekly injection routine that currently defines treatment with the blockbuster obesity drug — a meaningful step toward differentiating Novo's offering on convenience rather than efficacy alone.

The implant initiative is early-stage, but it signals the company's willingness to rethink how GLP-1 therapies are delivered. It also arrives as part of a broader push to defend market leadership against Eli Lilly, which has been chipping away at Novo's dominance in the obesity space.

The China Calculus

Days before the Vivani news surfaced, Novo disclosed that China's National Medical Products Administration had accepted its filing for the oral version of Wegovy for review. The submission follows Eli Lilly's late-2025 filing for its own oral candidate, orforglipron, meaning Novo enters the Chinese regulatory process with a timing disadvantage in one of the world's most promising obesity markets. Estimates suggest more than 65 percent of China's population could be overweight by 2030, making early market access there strategically vital.

The bull case rests on the possibility that oral Wegovy's clinical profile or regulatory pathway proves smoother than Lilly's, allowing Novo to close the gap despite the later submission. The bear case is equally straightforward: a prolonged review in China could cement Lilly's head start in a market where first-mover advantages tend to compound.

The Lilly Rivalry Intensifies

Competition between the two companies has moved beyond the clinic and into the courtroom. Novo has filed a federal lawsuit against Lilly, alleging that the competitor's national advertising for Zepbound and Mounjaro misleadingly compares its highest doses against older, lower doses of Novo's semaglutide. The legal escalation underscores how much is at stake as both companies fight for share in the GLP-1 category.

Lilly, for its part, has momentum on multiple fronts. The company generates roughly two-thirds of its revenue from GLP-1 products, became the first pharmaceutical firm to reach a USD 1 trillion market capitalization, and recently secured FDA approval for Mounjaro to reduce the risk of heart attacks and strokes — an indication expansion Novo has yet to match.

A Legal and Competitive Headwind

Novo also faces pressure from another direction: Russian drugmaker Geropharm is seeking court approval to use five of Novo's patents to produce generics of its obesity treatments. Meanwhile, the broader generic threat is already materializing in markets like South Africa, where a first generic GLP-1 product is available and 13 additional applications are under review. Novo has responded there with its own lower-priced offering, roughly 15 percent cheaper than the branded version — an acknowledgment that price erosion is no longer hypothetical.

The patent cliff looms larger still. According to industry analyses, products accounting for 77 percent of Novo's 2025 revenue will lose patent protection by 2033, with Ozempic's US exclusivity ending in the early 2030s. That timeline gives the company a finite window to establish new growth drivers.

Fundamentals Versus Sentiment

For all the bearish narrative, the valuation tells a different story. Novo Nordisk carries a net margin of 35.36 percent and trades at a price-to-earnings ratio of roughly 11 — figures that look inexpensive relative to its growth prospects and its primary competitor. The analyst consensus price target of USD 64.94 implies upside of more than 42 percent from recent levels, a gap that reflects either a compelling entry point or a market anticipating something the sell-side has yet to fully model.

Technical indicators are neutral: the stock's relative strength index sits at 43, suggesting neither overbought nor oversold conditions. The market appears to be waiting for clarity rather than positioning aggressively in either direction.

What Happens Next

The near-term catalyst calendar is dense. Novo's capital markets day on September 21 is expected to deliver strategic updates on the obesity pipeline and a growth outlook for 2027 — a year that has generated considerable debate over a potential revenue dip. The company's buyback program continues in the meantime, with 1,045,000 B-shares acquired between August 17 and 21 for approximately DKK 308.8 million, bringing cumulative repurchases under the current program to nearly 29.9 million shares worth DKK 8.39 billion.

The Chinese regulatory decision on oral Wegovy remains the most consequential unknown, though no timeline has been provided. Until that verdict lands, the shares are likely to remain a referendum on whether Novo can convert its pipeline breadth and cost discipline into a credible challenge to Lilly's momentum — or whether the valuation discount reflects a competitive reality that no amount of legal filings, device partnerships, or buyback activity can fully offset.